4 the nomenclature committee of the International Society of Amyloidosis,” Amyloid, vol. 17, no. 3-4, pp. 101–104, 2010. [3] K. Bodin, S. Ellmerich, M. C. Kahan et al., “Antibodies to human serum amyloid P component eliminate visceral amyloid deposits,” Nature, vol. 468, no. 7320, pp. 93–97, 2010. [4] J. S. Wall, S. J. Kennel, A. C. Stuckey et al., “Radioimmunode- tection of amyloid deposits in patients with AL amyloidosis,” Blood, vol. 116, no. 13, pp. 2241–2244, 2010. [5] L. M. Dember, P. N. Hawkins, B. P. C. Hazenberg et al., “Eprodisate for the treatment of renal disease in AA amyloidosis,” New England Journal of Medicine, vol. 356, no. 23, pp. 2349–2360, 2007. [6] M. Skinner, J. J. Anderson, R. Simms et al., “Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only,” American Journal of Medicine, vol. 100, no. 3, pp. 290–298, 1996. [7] R. A. Kyle, M. A. Gertz, P. R. Greipp et al., “A trial of three reg- imens for primary amyloidosis: colchicine alone, melphalan and prednisone, melphalan, prednisone, and colchicine,” New England Journal of Medicine, vol. 336, no. 17, pp. 1202–1207, 1997. [8] G. Palladini, V. Perfetti, L. Obici et al., “Association of melphalan and high-dose dexamethasone is eﬀective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation,” Blood, vol. 103, no. 8, pp. 2936–2938, 2004. [9] G. Palladini, P. Russo, M. Nuvolone et al., “Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis,” Blood, vol. 110, no. 2, pp. 787– 788, 2007. [10] S. Dietrich, S. O. Scho¨nland, A. Benner et al., “Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement,” Blood, vol. 116, no. 4, pp. 522–528, 2010. [11] D. Lebovic, J. Hoﬀman, B. M. Levine et al., “Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplan- tation and treated with oral melphalan and dexamethasone,” British Journal of Haematology, vol. 143, no. 3, pp. 369–373, 2008. [12] H. J. Lachmann, R. Gallimore, J. D. Gillmore et al., “Out- come in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy,” British Journal of Haematology, vol. 122, no. 1, pp. 78–84, 2003. [13] S. K. Kumar, S. V. Rajkumar, A. Dispenzieri et al., “Improved survival in multiple myeloma and the impact of novel therapies,” Blood, vol. 111, no. 5, pp. 2516–2520, 2008. [14] E. Kastritis, A. Anagnostopoulos, M. Roussou et al., “Treat- ment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone,” Haematologica, vol. 92, no. 10, pp. 1351–1358, 2007. [15] D. E. Reece, V. Sanchorawala, U. Hegenbart et al., “Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study,” Blood, vol. 114, no. 8, pp. 1489–1497, 2009. [16] A. D. Wechalekar, H. J. Lachmann, M. Oﬀer, P. N. Hawkins, and J. D. Gillmore, “Eﬃcacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease,” Haema- tologica, vol. 93, no. 2, pp. 295–298, 2008. [17] P. Moreau, V. Leblond, P. Bourquelot et al., “Prognostic factors for survival and response after high-dose therapy Bone Marrow Research and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients,” British Journal of Haematology, vol. 101, no. 4, pp. 766–769, 1998. [18] R. L. Comenzo, E. Vosburgh, R. H. Falk et al., “Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients,” Blood, vol. 91, no. 10, pp. 3662–3670, 1998. [19] M. A. Gertz, M. Q. Lacy, D. A. Gastineau et al., “Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL),” Bone Marrow Transplantation, vol. 26, no. 9, pp. 963–969, 2000. [20] M. T. Cibeira, V. Sanchorawala, D. C. Seldin et al., “Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients,” Blood, vol. 118, pp. 4346–4352, 2011. [21] M. A. Gertz, M. Q. Lacy, A. Dispenzieri et al., “Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006,” Bone Marrow Transplantation, vol. 46, no. 7, pp. 970–975, 2011. [22] M. A. Gertz, M. Q. Lacy, A. Dispenzieri et al., “Stem cell transplantation for the management of primary systemic amyloidosis,” American Journal of Medicine, vol. 113, no. 7, pp. 549–555, 2002. [23] A. Dispenzieri, M. A. Gertz, R. A. Kyle et al., “Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloi- dosis undergoing peripheral blood stem cell transplantation,” Blood, vol. 104, no. 6, pp. 1881–1887, 2004. [24] S. Kumar, A. Dispenzieri, J. A. Katzmann et al., “Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features,” Blood, vol. 116, no. 24, pp. 5126–5129, 2010. [25] S. Kumar, A. Dispenzieri, M. Q. Lacy et al., “Serum uric acid: novel prognostic factor in primary systemic amyloidosis,” Mayo Clinic Proceedings, vol. 83, no. 3, pp. 297–303, 2008. [26] G. Palladini, C. Campana, C. Klersy et al., “Serum N- terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis,” Circulation, vol. 107, no. 19, pp. 2440–2445, 2003. [27] N. Leung, T. R. Leung, S. S. Cha, A. Dispenzieri, M. Q. Lacy, and M. A. Gertz, “Excessive ﬂuid accumulation during stem cell mobilization: a novel prognostic factor of ﬁrst-year survival after stem cell transplantation in AL amyloidosis patients,” Blood, vol. 106, no. 10, pp. 3353–3357, 2005. [28] D. C. Seldin, J. J. Anderson, M. Skinner et al., “Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65,” Blood, vol. 108, no. 12, pp. 3945–3947, 2006. [29] M. A. Gertz, M. Q. Lacy, A. Dispenzieri et al., “Risk- adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate,” Bone Marrow Transplantation, vol. 34, no. 12, pp. 1025–1031, 2004. [30] M. A. Gertz, M. Q. Lacy, A. Dispenzieri et al., “Autologous stem cell transplant for immunoglobulin light chain amyloi- dosis: a status report,” Leukemia and Lymphoma, vol. 51, no. 12, pp. 2181–2187, 2010. [31] D. H. Vesole, W. S. Pe´rez, M. Akasheh, C. Boudreau, D. E. Reece, and C. N. Bredeson, “High-dose therapy and autol- ogous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research study,” Mayo Clinic Proceedings, vol. 81, no. 7, pp. 880–888, 2006.